For Healthcare Professionals
News
New! Real World Evidence across nearly 4,000 adult users shows best in class time below range with the lowest glycaemic variability, and strong time in range*
Join our Webinars
Join us for upcoming educational webinar series taking a closer look at Kaleido’s clinical evidence, technology, and how it can help optimise glycaemic control for your patients.
Feel free to bring your questions and any topics you’d like to discuss – we’ll shape the content together with you!
The Kaleido Difference
Proprietary Valve Microdosing Mechanism
Designed for precise, non-pressurised, and consistent insulin delivery
Reproducible insulin delivery
at the lowest bolus dose5
Basal and bolus dose accuracy
within +/- 5% of target6
All-Around Glycaemic Control in Real-World Use
Best-in-class* time below range; 1.23% time below 70 mg/dL (3.9 mmol/L); only 18 mins per day1; 0.21% time spent below 54 mg/dL (3.0 mmol/L); only 3 mins per day1
Lowest published Coefficient of Variation Data (CV); 28.7% median CV published in the real-world1,2
No compromise on strong time in range; 72.2% Median time in range meets consensus targets1,3,4
The Smallest, Lightest, Insulin Patch Pump In Its Class*
The Smallest, Lightest, Insulin Pump In Its Class*
Discreet, Personalised form factor weighs only 19 grams. Available in 10 colour combinations.
Smartphone controlled and connected with the Dexcom G7
Controlled from the Smartphone of the user.
Educational Materials
-
Software version 2.6.0 REV2Software version 2.6.0 REV2
-
Software version 2.6.0 REV1Software version 2.6.0 REV1
-
Software version 2.5.0Software version 2.5.0
-
Software version 2.4.0Software version 2.4.0
User guides Diabeloop DBLG1
User guide DBLG1 REV9 mg/dL (1.18)
User guide DBLG1 REV3 mmol/L (1.18)
More...
User guide DBLG1 REV9 mg/dL (1.18)
User guide DBLG1 REV3 mmol/L (1.18)
More...
-
User guide DBLG1 REV8 mg/dLUser guide DBLG1 REV8 mg/dL
-
User guide DBLG1 REV7 mg/dLUser guide DBLG1 REV7 mg/dL
-
User guide DBLG1 REV5 mg/dLUser guide DBLG1 REV5 mg/dL
-
Complete overview DBLG1 user guidesComplete overview DBLG1 user guides
User guides Diabeloop DBLG2
-
User guide DBLG2 REV 3 mg/dLUser guide DBLG2 REV 3 mg/dL
-
User guide DBLG2 REV 3 mmol/LUser guide DBLG2 REV 3 mmol/L
User guide Kaleido Controller
-
Kaleido ControllerKaleido Controller
Materials
-
Kaleido with DBLG2 BrochureKaleido with DBLG2 Brochure
-
Real-World EvidenceReal-World Evidence
-
Real-World Evidence AbstractReal-World Evidence Abstract
Contact
Kaleido
*Kaleido data on file. DCR 920379-02
1.Storms et al., “Glycaemic variability and real-world glycaemic control with the Kaleido insulin patch pump and DBLG1 AID algorithm,” EASD 2026 Late-Breaking Abstract LBA-26-4677-EASD. 2. Kaleido data on file 3. ADA Standards of Care; doi.org/10.2337/dc25-S006 4. doi: 10.2337/dc17-1600 5.Manufacturers’ IFU as of September 24, 2026. 6. Kaleido data on file. Real-World Evidence is based on users of Kaleido with Dexcom G6 and may not reflect outcomes with other compatible CGM systems, including Dexcom G7. Individual results may vary. The abstract comes from a conference abstract.
YourLoops, DBLG1 and DBLG2 are either registered trademarks or trademarks of Diabeloop SA in Europe and/or in other countries. Dexcom®, Dexcom G6® and Dexcom G7® are registered trademarks of Dexcom, Inc. in the United States and/or other countries. DBLG2 System is available only on prescription. DBLG2 System is indicated for Adults only. DBLG2 System is a CE 0123 marked medical device (except for configurations used exclusively during clinical investigations). Illustrations may vary depending on DBLG2 System configurations. Please be reminded that the User Manual for the medical device serves as the primary document for ensuring the safe operation of the system. Illustrations may differ from the actual product.